Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19226
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Burvenich, Ingrid J G | - |
dc.contributor.author | Parakh, Sagun | - |
dc.contributor.author | Gan, Hui K | - |
dc.contributor.author | Lee, Fook-Thean | - |
dc.contributor.author | Guo, Nancy | - |
dc.contributor.author | Rigopoulos, Angela | - |
dc.contributor.author | Lee, Sze-Ting | - |
dc.contributor.author | Gong, Sylvia | - |
dc.contributor.author | O'Keefe, Graeme J | - |
dc.contributor.author | Tochon-Danguy, Henri | - |
dc.contributor.author | Kotsuma, Masakatsu | - |
dc.contributor.author | Hasegawa, Jun | - |
dc.contributor.author | Senaldi, Giorgio | - |
dc.contributor.author | Scott, Andrew M | - |
dc.date | 2016-03-03 | - |
dc.date.accessioned | 2018-09-13T00:21:13Z | - |
dc.date.available | 2018-09-13T00:21:13Z | - |
dc.date.issued | 2016-06 | - |
dc.identifier.citation | Journal of Nuclear Medicine 2016; 57(6): 974-980 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/19226 | - |
dc.description.abstract | Subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase (EphA2) cell surface receptor is expressed in a range of epithelial cancers. This study evaluated the molecular imaging of EphA2 expression in vivo in mouse tumor models using SPECT/MR and PET/MR and a humanized anti-EphA2 antibody, DS-8895a. DS-8895a was labeled with (111)In, (125)I, and (89)Zr and assessed for radiochemical purity, immunoreactivity (Lindmo analysis), antigen-binding affinity (Scatchard analysis), and serum stability in vitro. In vivo biodistribution, imaging, and pharmacokinetic studies were performed with SPECT/MR and PET/MR. A dose-escalation study was also performed to determine EphA2 receptor saturability through tissue and imaging quantitative analysis. All conjugates demonstrated good serum stability and specific binding to EphA2-expressing cells in vitro. In vivo biodistribution studies showed high uptake of (111)In-CHX-A″-DTPA-DS-8895a and (89)Zr-Df-Bz-NCS-DS-8895a in EphA2-expressing xenograft models, with no specific uptake in normal tissues. In comparison, retention of (125)I-DS-8895a in tumors was lower because of internalization of the radioconjugate and dehalogenation. These results were confirmed by SPECT/MR and PET/MR. EphA2 receptor saturation was observed at the 30 mg/kg dose. Molecular imaging of tumor uptake of DS-8895a allows noninvasive measurement of EphA2 expression in tumors in vivo and determination of receptor saturation. (89)Zr-Df-Bz-NCS-DS-8895a is suited for human bioimaging trials on the basis of superior imaging characteristics and will inform DS-8895a dose assessment and patient response evaluation in clinical trials. | - |
dc.language.iso | eng | - |
dc.subject | 89Zr | - |
dc.subject | DS-8895a | - |
dc.subject | EphA2 | - |
dc.subject | bioimaging | - |
dc.subject | Cancer | - |
dc.title | Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Journal of Nuclear Medicine | - |
dc.identifier.affiliation | Translational Medicine and Clinical Pharmacology Department, Daiichi-Sankyo Co., Ltd., Tokyo, Japan | - |
dc.identifier.affiliation | Biologics Pharmacology Research Laboratories, Daiichi-Sankyo Co., Ltd., Tokyo, Japan | - |
dc.identifier.affiliation | Department of Translational Medicine and Clinical Pharmacology, Daiichi-Sankyo Pharma Development, Edison, New Jersey | - |
dc.identifier.affiliation | Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne, Australia | - |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Melbourne, Australia | en |
dc.identifier.affiliation | Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Melbourne, Australia | en |
dc.identifier.doi | 10.2967/jnumed.115.169839 | - |
dc.identifier.orcid | 0000-0003-3891-2489 | - |
dc.identifier.orcid | 0000-0002-6656-295X | - |
dc.identifier.pubmedid | 26940768 | - |
dc.type.austin | Journal Article | - |
dc.type.austin | Research Support, Non-U.S. Gov't | - |
local.name.researcher | Gan, Hui K | |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.